|The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma|
|Gong, Jifang1; Hu, Bing2; Zhang, Xiaotian1; Zhang, Fengchun3; Zhang, Jun4; Xu, Nong e5; Fan, Qingxia6; Bai, Yuxian7; Jiao, Shunchang8; Wang, Jinwan9; Bai, Chunmei10; Zheng, Leizhen11; Shi, Yingqiang12; Liu, Yunpeng13; Liang, Jun14; Hu, Guoqing15; Cheng, Ying16; Xu, Ruihua17; Bai, Yu18; Shen, Lin1|
|WOS标题词||Science & Technology|
Background. The efficacy and toxicity of paclitaxel plus capecitabine (PX) as first-line treatment in advanced gastric cancer (AGC) was evaluated.
Methods. Patients with previously untreated AGC were included. PX was given every 3 weeks until a maximum of six cycles or progression. Capecitabine monotherapy was continued for patients without disease progression. The primary endpoint was progression-free survival, and secondary endpoints were objective response rate, overall survival (OS), and safety.
Results. Overall, 194 patients were treated per protocol and one patient was excluded because of allergy to paclitaxel. Response was evaluated in 175 patients, with an objective response rate of 34.8%. After a median follow-up of 33.2 months, disease progression was observed in 141 patients, 137 died, and 16 were lost to follow-up, with progression-free survival of 188 days and OS of 354 days. In multivariate Cox regression analysis, no factor remained an independent predictor of OS. Forty-five patients who received capecitabine monotherapy after PX had longer OS (531 days). Adverse events were mild (Fig. 1), and the most common grade 3-4 toxicities were leucopenia and neutropenia.
Conclusion. PX as a first-line treatment has promising efficacy in AGC. Based on these data, a phase III study has been launched for further investigation.
|项目编号||81172110 ; 2006AA 02A 402-B02 ; 2012AA 02A 504 ; Z11110706730000|
|资助机构||National Natural Science Foundation of China ; National High Technology Research and Development Program ; Beijing Municipal Science & ; Technology Commission Program|
|作者单位||1.Peking Univ, Canc Hosp & Inst, Beijing 100142, Peoples R China|
2.Anhui Prov Hosp, Hefei, Peoples R China
3.Suzhou Kowloon Hosp, Suzhou, Peoples R China
4.Ruijin Hosp, Shanghai, Peoples R China
5.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
6.Zhengzhou Univ, Affiliated Hosp 1, Henan, Peoples R China
7.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
8.Chinese Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
9.Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China
10.Beijing Union Med Coll Hosp, Beijing, Peoples R China
11.Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China
12.Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
13.China Med Univ, Hosp 1, Shenyang, Peoples R China
14.Qingdao Univ, Coll Med, Affiliated Hosp, Qingdao 266071, Peoples R China
15.Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
16.Jilin Prov Tumor Hosp, Changchun, Peoples R China
17.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
18.Peking Univ, Hosp 1, Beijing 100142, Peoples R China
|Gong, Jifang,Hu, Bing,Zhang, Xiaotian,et al. The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma[J]. ONCOLOGIST,2014,19(2):173-174.|
|APA||Gong, Jifang.,Hu, Bing.,Zhang, Xiaotian.,Zhang, Fengchun.,Zhang, Jun.,...&Shen, Lin.(2014).The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma.ONCOLOGIST,19(2),173-174.|
|MLA||Gong, Jifang,et al."The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma".ONCOLOGIST 19.2(2014):173-174.|